The move comes after the Sweden-based orthobiologic producer announced plans to develop its own US-based distribution network, which includes cancelling its distribution agreement with Zimmer Biomet.
“Today’s announcement highlights the importance of Bonesupport taking control of its commercial platform in the US. The evaluation of potential distribution partners is progressing to plan. We expect to have a strong coverage of the US market in place in late October, positioning us to create more direct and stronger relationships with our US customer base. This enhanced commercial platform will allow us to successfully market our highly differentiated products, particularly Cerament G, which we aim to launch in the US market in 2021,” CEO Emil Billbäck said in a press release.
BoneSupport said that its in-market sales of Cerament in the US are “continuing to show good growth” with increasing demand which is being met by Zimmer Biomet’s current inventory.
The company specified that Zimmer Biomet will retain the rights to sell and distribute Cerament BVF exclusively until October 2018, and non-exclusively until April 20, 2019.
Last month, BoneSupport announced plans to expand its sales force, adding an additional 13 sales representatives in “key markets” this year.
At DeviceTalks Boston, Tyler Shultz will give attendees an inside look at Theranos and how he was able to sound the alarm after he realized the company was falling apart. Shultz will take attendees behind the story that everyone is talking about: the rise and fall of Elizabeth Holmes and her diagnostic company, Theranos.
Join Shultz and 1,000+ medical device professionals at the 8th annual DeviceTalks Boston.